{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/delirium/prescribing-information/lorazepam/","result":{"pageContext":{"chapter":{"id":"4faac93d-8b62-5294-933f-214a1155f283","slug":"lorazepam","fullItemName":"Lorazepam","depth":2,"htmlHeader":"<!-- begin field 928de314-8d02-4766-824f-af89c25d8cf8 --><h2>Lorazepam</h2><!-- end field 928de314-8d02-4766-824f-af89c25d8cf8 -->","summary":"","htmlStringContent":"<!-- begin item 6198f8ee-f83b-43f6-8fdf-1c64b455cb8d --><!-- begin field 47c115eb-6e8a-4ddd-87de-a1a7d9a14db5 -->Lorazepam (off-label indication) should only be used for the treatment of challenging behaviour associated with delirium on the advice of a specialist.<br><!-- end field 47c115eb-6e8a-4ddd-87de-a1a7d9a14db5 --><!-- end item 6198f8ee-f83b-43f6-8fdf-1c64b455cb8d -->","topic":{"id":"6b89f111-d1d1-510e-8846-71e15c389f06","topicId":"64430de8-33e7-409d-b433-725a712a6f41","topicName":"Delirium","slug":"delirium","lastRevised":"Last revised in April 2020","chapters":[{"id":"0455d257-6ef6-5e50-9dc0-21780666b8e7","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"a71db69b-5a97-544a-a806-ec82704f3907","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"58e84228-4844-5721-859b-91d58faa7eb6","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"999affe9-788e-52a9-83c8-ad933103eeb5","slug":"changes","fullItemName":"Changes"},{"id":"29c67640-566b-5fa4-8966-5b08ca667756","slug":"update","fullItemName":"Update"}]},{"id":"6dddaa0e-c24c-5f4e-8044-6a3229f859df","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"7e8bf385-fd9a-544a-bc9d-375555c17ab0","slug":"goals","fullItemName":"Goals"},{"id":"8f18311c-4fad-5969-8a94-addcca05fb64","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"b45b0c3d-03c0-5300-b0c4-62ccd106e229","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"7b7d4906-4705-52ba-a39f-ecfb7c5d1e98","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"331ceb18-88fc-530e-aa48-bae28dde9901","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"558ba6d3-06ab-5370-b6b7-09548f2c3c8e","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"b6e24e45-958a-5052-800a-ef5c6f140719","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"2b925b35-d493-5d01-bb58-9f18c37e1357","slug":"definition","fullItemName":"Definition"},{"id":"27bd26a5-66e1-5d51-a992-7e06e6a3cdfa","slug":"predisposing-factors","fullItemName":"Predisposing factors"},{"id":"c3582ffa-e505-5580-a3fa-f6a04f0938cc","slug":"precipitating-factors","fullItemName":"Precipitating factors"},{"id":"44402d85-ef9c-562b-ad2c-e99c0d8c60a7","slug":"prevalence","fullItemName":"Prevalence"},{"id":"799dcaa5-4683-5bf0-a9d7-dfc860ab7c81","slug":"complications","fullItemName":"Complications"},{"id":"ca4b25bd-2486-55a7-92c0-c39322caa272","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"993580f3-4201-5dd5-8a6d-f64de509d328","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"3f7d0746-b45f-5f52-8e49-7effac5e3547","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"f84af6b7-85fc-56aa-9554-29d1231a7fd1","slug":"assessment","fullItemName":"Assessment"},{"id":"cc3618cd-d41e-5719-939a-78ed0be305e4","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"9d04a09f-9612-570d-aeb7-c0121bda09c4","fullItemName":"Management","slug":"management","subChapters":[{"id":"81f2aa66-ed46-54f0-80b5-4dfca4afb344","slug":"management","fullItemName":"Scenario: Management"},{"id":"58bb812f-7b3c-57be-aab1-8ae228aff1d1","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"769a3265-9e21-5508-b937-bf6aa4a8f378","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"fa09afb1-cc68-5f68-afbe-7486c91a5ed4","slug":"haloperidol","fullItemName":"Haloperidol"},{"id":"4faac93d-8b62-5294-933f-214a1155f283","slug":"lorazepam","fullItemName":"Lorazepam"},{"id":"c02516c6-89cb-5dc3-99db-17f261f5f80e","slug":"levomepromazine","fullItemName":"Levomepromazine"}]},{"id":"cd438911-3d3a-51dd-8455-3e41c260dd60","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"cec2028c-5183-50fb-9bb7-f20aea64a152","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a5323429-af72-5d8b-a251-0715c1a15bba","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"26c6273a-60c7-5b9a-b49f-9f9fbb623941","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"b70aed75-14ce-57f4-b2b0-474fa4480d56","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"c5faba8c-4118-59d9-af20-8c8d52a89eb2","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"71e02a81-885f-515f-8852-109bc9b5580f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"51d66a08-1fc6-5593-8764-c9d4e547d827","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"769a3265-9e21-5508-b937-bf6aa4a8f378","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"a26f6b5a-f3da-556c-bbaa-52c557c8cd0c","slug":"dosage","fullItemName":"Dosage","depth":3,"htmlHeader":"<!-- begin field e4805a3b-03f1-4f72-98e3-2adbb75f0847 --><h3>What dose of lorazepam should I prescribe?</h3><!-- end field e4805a3b-03f1-4f72-98e3-2adbb75f0847 -->","summary":"","htmlStringContent":"<!-- begin item 289e5475-8fb2-46cb-bdd2-462f69d1af2b --><!-- begin field dae52f1c-bdd9-4c10-9d05-9d756a90e9e2 --><ul><li><strong>Dosage:</strong><ul><li>Start at the lowest possible dose (0.5–1 mg) orally and titrate in increments if necessary after an interval of two hours until there is a clinical response [<a class=\"bibliography-reference internal-reference\" href=\"/topics/delirium/references/\">Royal College of Physicians and British Geriatrics Society, 2006b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/delirium/references/\">Inouye, 2014</a>].</li><li>The maximum dose in 24 hours should not exceed 2 mg [<a class=\"bibliography-reference internal-reference\" href=\"/topics/delirium/references/\">Healthcare Improvement Scotland, 2014</a>].</li></ul></li><li><strong>One-to-one care of the person </strong>should be available while the dose is titrated in a controlled and safe manner [<a class=\"bibliography-reference internal-reference\" href=\"/topics/delirium/references/\">Royal College of Physicians and British Geriatrics Society, 2006b</a>].</li><li><strong>Review the person regularly and discontinue lorazepam as soon as possible</strong> — aim to reduce and stop lorazepam after 24–48 hours [<a class=\"bibliography-reference internal-reference\" href=\"/topics/delirium/references/\">Royal College of Physicians and British Geriatrics Society, 2006b</a>].</li></ul><!-- end field dae52f1c-bdd9-4c10-9d05-9d756a90e9e2 --><!-- end item 289e5475-8fb2-46cb-bdd2-462f69d1af2b -->","subChapters":[]},{"id":"2e174ab7-47d1-5312-98af-0d14b97a4fba","slug":"adverse-drug-effects","fullItemName":"Adverse drug effects","depth":3,"htmlHeader":"<!-- begin field f820efe2-0f47-4414-be56-4aa9c772573a --><h3>What are the adverse effects of lorazepam?</h3><!-- end field f820efe2-0f47-4414-be56-4aa9c772573a -->","summary":"","htmlStringContent":"<!-- begin item 6c75be47-3ac8-4383-9ffa-4643451bcbf6 --><!-- begin field 92b43eee-86f6-45f9-9631-19093f6fdc94 --><ul><li><strong>The most frequently reported adverse effects associated with benzodiazepines include:</strong><ul><li>Daytime drowsiness.</li><li>Dizziness.</li><li>Muscle weakness.</li><li>Ataxia.</li></ul></li><li><strong>Less commonly reported adverse effects include:</strong><ul><li><strong>Blood and lymphatic system disorders</strong> such as thrombocytopenia, leucopenia, agranulocytosis, and pancytopenia.</li><li><strong>Immune system disorders</strong> such as hypersensitivity including anaphylaxis/anaphylactoid reactions.</li><li><strong>Endocrine disorders</strong> such as the syndrome of inappropriate antidiuresis (SIAD), hyponatraemia.</li><li><strong>Psychiatric disorders </strong>such as confusion (especially in the elderly), depression, numbed emotions, disinhibition, euphoria, dependence, and suicidal ideation/attempt. Paradoxical reactions such as restlessness, agitation, irritability, aggressiveness, delusion, rage, insomnia, nightmares, hallucinations, psychoses, sexual arousal, and inappropriate behaviour have been occasionally reported during use. </li><li><strong>Disorders of the central nervous system</strong> such as daytime drowsiness, light-headedness, sedation, ataxia (especially in the elderly), headache, reduced alertness, dysarthria/slurred speech, transient anterograde amnesia or memory impairment, tremor, extrapyramidal reactions, coma.</li><li><strong>Eye disorders</strong> such as visual disturbances (diplopia, blurred vision).</li><li><strong>Vascular disorders</strong> such as hypotension.</li><li><strong>Respiratory and mediastinal disorders</strong> such as apnoea, worsening of sleep apnoea, worsening of obstructive pulmonary disease, respiratory depression.</li><li><strong>Gastrointestinal disorders</strong> such as nausea, constipation, salivation changes.</li><li><strong>Hepatobiliary disorders</strong> such as abnormal liver function tests (increases in bilirubin, transaminases, alkaline phosphatase), jaundice.</li><li><strong>Skin disorders</strong> such as rashes, allergic dermatitis.</li><li><strong>Musculoskeletal disorders</strong> such as muscle weakness.</li><li><strong>Reproductive system disorders</strong> such as erectile dysfunction.</li><li><strong>General symptoms</strong> such as asthenia, fatigue, hypothermia.</li><li><strong>Drug withdrawal symptoms</strong> — such as headache, muscle pain, anxiety, tension, depression, insomnia, restlessness, confusion, irritability, sweating, and 'rebound' symptoms, where symptoms that led to treatment with benzodiazepines recur in an enhanced form following discontinuation of benzodiazepines.</li></ul></li></ul><p><strong>People who are taking benzodiazepines and intend to drive should be given the following advice </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/delirium/references/\">Department for Transport, 2014</a>]<strong>:</strong> </p><ul><li>Do not drive if you feel drowsy, dizzy, unable to concentrate or make decisions. It is now an offence to drive if you have more than a specified amount of benzodiazepine in your body whether your driving is impaired or not. </li><li>Roadside drug screening tests have been introduced into the UK since March 2015. These test the saliva for drugs that impair driving. If you have a positive roadside drug test for benzodiazepines, the police may ask you to provide a blood sample to measure the amount of benzodiazepine in your body. <ul><li>If you are found to have more than the specified amount of benzodiazepine, as long as your driving is not impaired, you are taking your medicine on the advice of your GP, or your pharmacist, you will be able to raise a 'statutory defence' and the police may not prosecute you. </li></ul></li><li>It may be helpful to keep evidence with you (that you are taking a benzodiazepine in accordance with medical advice) while you are driving.<ul><li>Suitable evidence may include: your medication box with the pharmacy label on, or the other half of your prescription with the list of medicines prescribed by your doctor.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/delirium/references/\">ABPI, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/delirium/references/\">BNF 71, 2016</a>]</p><!-- end field 92b43eee-86f6-45f9-9631-19093f6fdc94 --><!-- end item 6c75be47-3ac8-4383-9ffa-4643451bcbf6 -->","subChapters":[]},{"id":"5bbebea1-f80c-5c7b-9377-582fef53a84a","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field eb750b6d-5203-4d14-a639-1f99828dd502 --><h3>What are the contraindications and cautions with lorazepam?</h3><!-- end field eb750b6d-5203-4d14-a639-1f99828dd502 -->","summary":"","htmlStringContent":"<!-- begin item 200f6b08-391e-4da8-8952-ed2e874a32ff --><!-- begin field 1905677c-2f8f-4a50-b2d0-d4a7ac4df031 --><ul><li><strong>Do not prescribe lorazepam if a person has or is suspected of having:</strong><ul><li>Hypersensitivity to benzodiazepines or to any of the other ingredients.<ul><li>This includes people with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption.</li></ul></li><li>Respiratory depression, marked neuromuscular respiratory weakness (including myasthenia gravis), acute pulmonary insufficiency, or sleep apnoea syndrome.</li><li>Chronic psychosis, phobic or obsessional states.</li><li>Severe hepatic impairment (may precipitate encephalopathy).</li><li>Hyperkinesis.</li><li>Depression or anxiety with depression — benzodiazepines should not be used alone in depression or depression with anxiety as they may precipitate suicide.</li></ul></li><li><strong>Prescribe lorazepam with caution in people who:</strong><ul><li>Are frail or elderly.</li><li>Are hypotensive — benzodiazepines should be used with caution where a drop in blood pressure might lead to cardiovascular or cerebrovascular complications. This is particularly important in elderly people. </li><li>Have acute narrow-angle glaucoma. </li><li>Have impaired renal or hepatic function.</li><li>Have chronic respiratory insufficiency.</li><li>Have taken alcohol or other central nervous system (CNS) depressants — tolerance will be reduced — either avoid these substances or reduce the dose.</li><li>Have a history of drug or alcohol dependence.</li><li>Have organic brain changes. </li><li>Have a personality disorder (such as dependent, avoidant, or obsessive-compulsive) — may increase risk of dependence. </li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/delirium/references/\">ABPI, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/delirium/references/\">BNF 71, 2016</a>]</p><!-- end field 1905677c-2f8f-4a50-b2d0-d4a7ac4df031 --><!-- end item 200f6b08-391e-4da8-8952-ed2e874a32ff -->","subChapters":[]},{"id":"7f29ce04-afe8-5e25-93c8-03d7a960932b","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 441b3863-7a7b-4ec8-b415-c1f814e93c98 --><h3>What drug interactions can occur with lorazepam?</h3><!-- end field 441b3863-7a7b-4ec8-b415-c1f814e93c98 -->","summary":"","htmlStringContent":"<!-- begin item 746ac911-d60b-4cc0-a5ab-fd033d409b03 --><!-- begin field f5b0650a-caf7-4285-8737-7bbacf945698 --><p><strong>Lorazepam may interact with:</strong></p><ul><li><strong>Alcohol</strong> — lorazepam should not be used together with alcohol due to enhanced sedative effects; impaired ability to drive/operate machinery.</li><li><strong>Antiretrovirals</strong><ul><li>HIV-protease inhibitors — avoid concomitant use (increased risk of prolonged sedation).</li><li>Zidovudine — increased zidovudine clearance by lorazepam.</li></ul></li><li><strong>Centrally-acting drugs</strong> — central depressive effect may be enhanced if lorazepam is combined with drugs such as neuroleptics, antipsychotics, tranquillizers, antidepressants, hypnotics, analgesics, anaesthetics, barbiturates, and sedative antihistamines. The elderly may require special supervision. </li><li><strong>Anti-epileptic drugs</strong> — reduction and elevation of drug levels have been reported. Phenobarbital taken concomitantly may result in an additive central nervous system (CNS) effect. Valproate may inhibit the glucuronidation of lorazepam (increased serum levels causing an increased risk of drowsiness).</li><li><strong>Opiate analgesics</strong> — enhancement of euphoria may lead to increased psychological dependence.   </li><li><strong>Clozapine</strong> — serious adverse effects such as marked sedation, hypotension, ataxia, delirium, and respiratory arrest have been reported when given concurrently with lorazepam.</li><li><strong>Drugs enhancing sedation</strong> include cisapride, lofexidine, nabilone, sodium oxybate, disulfiram, and the muscle relaxants baclofen and tizanidine. Avoid concomitant use.</li><li><strong>Compounds that affect hepatic enzymes</strong> (particularly cyctochrome P450):<ul><li>Inhibitors (for example cimetidine, isoniazid; erythromycin; omeprazole; esomeprazole) reduce clearance and may potentiate the action of benzodiazepines. Itraconazole, ketoconazole and to a lesser extent fluconazole and voriconazole are potent inhibitors of the cytochrome P450 isoenzyme CYP3A4 and may increase plasma levels of benzodiazepines. The effects of benzodiazepines may be increased and prolonged by concomitant use. A dose reduction of the benzodiazepine may be required.</li><li>Inducers (for example rifampicin) may increase clearance of benzodiazepines.</li></ul></li><li><strong> Antihypertensives, vasodilators, and diuretics </strong>— enhanced hypotensive effect with angiotensin-converting enzyme (ACE) inhibitors, alpha-blockers, angiotensin-II receptor antagonists (AIIRAs), calcium-channel blockers, adrenergic neurone blockers, beta-blockers, moxonidine, nitrates, hydralazine, minoxidil, sodium nitroprusside, and diuretics.  Enhanced sedative effect with alpha-blockers or moxonidine.</li><li><strong>Dopaminergics</strong> — possible antagonism of the effect of levodopa.</li><li><strong>Antacids</strong> — concurrent use may delay absorption of lorazepam.</li><li><strong>Theophylline/aminophylline</strong> — increases metabolism of lorazepam which possibly reduces its effect.</li><li><strong>Caffeine </strong>— concurrent use may result in reduced sedative and anxiolytic effects of lorazepam. </li><li><strong>Grapefruit juice</strong> — inhibition of CYP3A4 may increase the plasma concentration of lorazepam (possible increased sedation and amnesia). This interaction may be of little significance in healthy people, but other factors such as old age or liver cirrhosis may increase the risk of adverse events with concurrent use.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/delirium/references/\">ABPI, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/delirium/references/\">BNF 71, 2016</a>]</p><!-- end field f5b0650a-caf7-4285-8737-7bbacf945698 --><!-- end item 746ac911-d60b-4cc0-a5ab-fd033d409b03 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}